ePI Bundle example 1 - XML Representation - European Medicines Regulatory Network (EMRN) Electronic Product Information (ePI) Implementation Guide v1.0.0

European Medicines Regulatory Network (EMRN) Electronic Product Information (ePI) Implementation Guide - Local Development build (v1.0.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
: ePI Bundle example 1 - XML Representation

Raw xml | Download

<Bundle xmlns="http://hl7.org/fhir">
  <id value="b99c95f8-bb0b-ef11-9f8a-000d3aa845fb"/>
  <meta>
    <profile
             value="http://ema.europa.eu/fhir/StructureDefinition/EUEpiBundle"/>
  </meta>
  <identifier>
    <system value="http://ema.europa.eu/fhir/epiDocument"/>
    <value value="b99c95f8-bb0b-ef11-9f8a-000d3aa845fb"/>
  </identifier>
  <type value="document"/>
  <timestamp value="2024-05-08T09:21:26.034+00:00"/>
  <entry>
    <fullUrl value="urn:uuid:fe63fd6a-afe8-4b61-a203-0cf4a69ffb60"/>
    <resource>
      <Composition>
        <id value="fe63fd6a-afe8-4b61-a203-0cf4a69ffb60"/>
        <meta>
          <profile
                   value="http://ema.europa.eu/fhir/StructureDefinition/EUEpiComposition"/>
        </meta>
        <language value="en"/>
        <text>
          <status value="additional"/>
          <div xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">electronic Product Information (ePI) document</div>
        </text>
        <contained>
          <Binary>
            <id value="d15f2fb1-ca0b-ef11-9f89-7c1e5212dc19"/>
            <contentType value="image/png"/>
            <data
                  value="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"/>
          </Binary>
        </contained>
        <contained>
          <Binary>
            <id value="d15f2fb1-ca0b-ef11-9f89-7c1e5212dc20"/>
            <contentType value="image/png"/>
            <data
                  value="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"/>
          </Binary>
        </contained>
        <extension
                   url="http://ema.europa.eu/fhir/StructureDefinition/ext-epi-image-reference">
          <valueReference>
            <reference value="#d15f2fb1-ca0b-ef11-9f89-7c1e5212dc19"/>
          </valueReference>
        </extension>
        <extension
                   url="http://ema.europa.eu/fhir/StructureDefinition/ext-epi-image-reference">
          <valueReference>
            <reference value="#d15f2fb1-ca0b-ef11-9f89-7c1e5212dc20"/>
          </valueReference>
        </extension>
        <identifier>
          <system value="http://ema.europa.eu/fhir/epiDocument"/>
          <value value="b99c95f8-bb0b-ef11-9f8a-000d3aa845fb"/>
        </identifier>
        <status value="final"/>
        <type>
          <coding>
            <system
                    value="http://ema.europa.eu/fhir/CodeSystem/100000155531"/>
            <code value="100000155532"/>
            <display value="Summary of Product Characteristics"/>
          </coding>
        </type>
        <date value="2024-05-08"/>
        <author>
          <identifier>
            <value value="European Medicines Agency (EMA)"/>
          </identifier>
        </author>
        <title value="EPI SUMMARY OF PRODUCT CHARACTERISTICS EXAMPLE"/>
        <section>
          <title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
          <code>
            <coding>
              <system
                      value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
              <code value="200000029791"/>
              <display value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
            </coding>
          </code>
          <section>
            <title value="1. NAME OF THE MEDICINAL PRODUCT"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029792"/>
                <display value="1. NAME OF THE MEDICINAL PRODUCT"/>
              </coding>
            </code>
            <text>
              <status value="additional"/>
              <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX from CompanyY 100&#160;mg hard capsules</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY 400&#160;mg hard capsules</p></div>
            </text>
          </section>
          <section>
            <title value="2. QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029793"/>
                <display value="2. QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
              </coding>
            </code>
            <text>
              <status value="additional"/>
              <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY 100&#160;mg hard capsules</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Each hard capsule contains 100&#160;mg of X.</p><p style="margin: 0cm 0cm 0.0001pt; text-align: justify; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY 400&#160;mg hard capsules</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Each hard capsule contains 400&#160;mg of X.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">For the full list of excipients, see section 6.1.</p></div>
            </text>
          </section>
          <section>
            <title value="3. PHARMACEUTICAL FORM"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029797"/>
                <display value="3. PHARMACEUTICAL FORM"/>
              </coding>
            </code>
            <text>
              <status value="additional"/>
              <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hard capsule.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY 100&#160;mg hard capsules</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Non transparent orange capsules with black marking 7629 on capsule body and black marking Company Y on capsule cap. The content of the capsule is white to light yellow granulated powder.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The length of the capsule is from 19.1 mm to 19.7 mm and the width is 6.91 mm.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY 400&#160;mg hard capsules</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Non transparent orange capsules with black marking 7630 on capsule body and black marking Company Y on capsule cap. The content of the capsule is white to light yellow granulated powder.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The length of the capsule is from 23.0 mm to 23.6 mm and the width is 8.53 mm.</p></div>
            </text>
          </section>
          <section>
            <title value="4. CLINICAL PARTICULARS"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029798"/>
                <display value="4. CLINICAL PARTICULARS"/>
              </coding>
            </code>
            <section>
              <title value="4.1 Therapeutic indications"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029799"/>
                  <display value="4.1 Therapeutic indications"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY is indicated for the treatment of</p><ul style="margin-bottom: 0cm; margin-top: 0px;"><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr&#8209;abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.</li><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon&#8209;alpha therapy, or in accelerated phase or blast crisis.</li><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.</li><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">adult patients with relapsed or refractory Ph+ ALL as monotherapy.</li><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.</li><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR&#945; rearrangement.</li></ul><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The effect of X on the outcome of bone marrow transplantation has not been determined.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY <span style="color: black;">is indicated for</span></p><ul style="margin-bottom: 0cm; margin-top: 0px;"><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).</li><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.</li><li style="line-height: normal; margin: 0cm 0cm 0.0001pt 0px; font-size: 11pt; font-family: 'Times New Roman', serif;">the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.</li></ul><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In adult and paediatric patients, the effectiveness of X is based on overall haematological and cytogenetic response rates and progression&#8209;free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with X in patients with MDS/MPD associated with PDGFR gene re&#8209;arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.</p></div>
              </text>
            </section>
            <section>
              <title value="4.2 Posology and method of administration"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029800"/>
                  <display value="4.2 Posology and method of administration"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p>Therapy should be initiated by a physician experienced in the treatment of patients with haematological malignancies and malignant sarcomas, as appropriate.</p></div>
              </text>
              <section>
                <title value="Posology"/>
                <code>
                  <coding>
                    <system
                            value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                    <code value="200000029801"/>
                    <display value="Posology"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/>
                  <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Content on posology</p></div>
                </text>
              </section>
              <section>
                <title value="Method of administration"/>
                <code>
                  <coding>
                    <system
                            value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                    <code value="200000029803"/>
                    <display value="Method of administration"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/>
                  <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Content on method of administration</p></div>
                </text>
              </section>
            </section>
            <section>
              <title value="4.3 Contraindications"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029805"/>
                  <display value="4.3 Contraindications"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</p></div>
              </text>
            </section>
            <section>
              <title value="4.4 Special warnings and precautions for use"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029806"/>
                  <display
                           value="4.4 Special warnings and precautions for use"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">When X is co&#8209;administered with other medicinal products, there is a potential for drug interactions. Caution should be used when taking X with protease inhibitors, azole antifungals, certain macrolides, CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5).</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Concomitant use of X and medicinal products that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or <em>Hypericum perforatum</em>, also known as St. John&#8217;s Wort) may significantly reduce exposure to X, potentially increasing the risk of therapeutic failure. Therefore, concomitant use of strong CYP3A4 inducers and X should be avoided (see section 4.5).</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hypothyroidism</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with X (see section 4.5). Thyroid&#8209;stimulating hormone (TSH) levels should be closely monitored in such patients.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hepatotoxicity</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Metabolism of X is mainly hepatic, and only 13% of excretion is through the kidneys. In patients with hepatic dysfunction (mild, moderate or severe), peripheral blood counts and liver enzymes should be carefully monitored (see sections 4.2, 4.8 and 5.2). It should be noted that GIST patients may have hepatic metastases which could lead to hepatic impairment.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Cases of liver injury, including hepatic failure and hepatic necrosis, have been observed with X. When X is combined with high dose chemotherapy regimens, an increase in serious hepatic reactions has been detected. Hepatic function should be carefully monitored in circumstances where X is combined with chemotherapy regimens also known to be associated with hepatic dysfunction (see sections 4.5 and 4.8).</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Fluid retention</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Occurrences of severe fluid retention (pleural effusion, oedema, pulmonary oedema, ascites, superficial oedema) have been reported in approximately 2.5% of newly diagnosed CML patients taking X. Therefore, it is highly recommended that patients be weighed regularly. An unexpected rapid weight gain should be carefully investigated and if necessary appropriate supportive care and therapeutic measures should be undertaken. In clinical trials, there was an increased incidence of these events in the elderly and those with a prior history of cardiac disease. Therefore, caution should be exercised in patients with cardiac dysfunction.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Patients with cardiac disease</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Patients with cardiac disease, risk factors for cardiac failure or history of renal failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac or renal failure should be evaluated and treated.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">In patients with hypereosinophilic syndrome (HES) with occult infiltration of HES cells within the myocardium, isolated cases of cardiogenic shock/left ventricular dysfunction have been associated with </span><span style="font-size: 11.0pt; color: black;">HES cell degranulation upon </span><span style="font-size: 11.0pt;">the initiation of X therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding X. As cardiac adverse events have been reported uncommonly with X, a careful assessment of the benefit/risk of X therapy should be considered in the HES/CEL population before treatment initiation.</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Myelodysplastic/myeloproliferative diseases with PDGFR gene re&#8209;arrangements could be associated with high eosinophil levels. Evaluation by a cardiology specialist, performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/CEL, and in patients with MDS/MPD associated with high eosinophil levels before X is administered. If either is abnormal, follow&#8209;up with a cardiology specialist and the prophylactic use of systemic steroids (1&#8209;2&#160;mg/kg) for one to two weeks concomitantly with X should be considered at the initiation of therapy.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Gastrointestinal haemorrhage</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intra&#8209;tumoural haemorrhages were reported (see section 4.8). Based on the available data, no predisposing factors (e.g. tumour size, tumour location, coagulation disorders) have been identified that place patients with GIST at a higher risk of either type of haemorrhage. Since increased vascularity and propensity for bleeding is a part of the nature and clinical course of GIST, standard practices and procedures for the monitoring and management of haemorrhage in all patients should be applied.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In addition, gastric antral vascular ectasia (GAVE), a rare cause of gastrointestinal haemorrhage, has been reported in post-marketing experience in patients with CML, ALL and other diseases (see section 4.8). When needed, discontinuation of ProductX CompanyY treatment may be considered.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Tumour lysis syndrome</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Due to the possible occurrence of tumour lysis syndrome (TLS), correction of clinically significant dehydration and treatment of high uric acid levels are recommended prior to initiation of X (see section 4.8).</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Hepatitis B reactivation</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors. Some cases resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Patients should be tested for HBV infection before initiating treatment with ProductX CompanyY. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with ProductX CompanyY should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Phototoxicity</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Exposure to direct sunlight should be avoided or minimised due to the risk of phototoxicity associated with X treatment. Patients should be instructed to use measures such as protective clothing and sunscreen with high sun protection factor (SPF).</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Thrombotic microangiopathy</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">BCR-ABL tyrosine kinase inhibitors (TKIs) have been associated with thrombotic microangiopathy (TMA), including individual case reports for ProductX CompanyY (see section&#160;4.8). If laboratory or clinical findings associated with TMA occur in a patient receiving ProductX CompanyY , treatment should be discontinued and thorough evaluation for TMA, including ADAMTS13 activity and anti-ADAMTS13-antibody determination, should be completed. If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with ProductX CompanyY should not be resumed.</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Laboratory tests</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Complete blood counts must be performed regularly during therapy with X. Treatment of CML patients with X has been associated with neutropenia or thrombocytopenia. However, the occurrence of these cytopenias is likely to be related to the stage of the disease being treated and they were more frequent in patients with accelerated phase CML or blast crisis as compared to patients with chronic phase CML. Treatment with X may be interrupted or the dose may be reduced, as recommended in section 4.2.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Liver function (transaminases, bilirubin, alkaline phosphatase) should be monitored regularly in patients receiving X.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In patients with impaired renal function, X plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha&#8209;acid&#160;glycoprotein (AGP), an X&#8209;binding protein, in these patients. Patients with renal impairment should be given the minimum starting dose. Patients with severe renal impairment should be treated with caution. The dose can be reduced if not tolerated (see section 4.2 and 5.2).</p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Long-term treatment with X may be associated with a clinically significant decline in renal function. Renal function should, therefore, be evaluated prior to the start of X therapy and closely monitored during therapy, with particular attention to those patients exhibiting risk factors for renal dysfunction. If renal dysfunction is observed, appropriate management and treatment should be prescribed in accordance with standard treatment guidelines.</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Paediatric population</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">There have been case reports of growth retardation occurring in children and pre&#8209;adolescents receiving X. In an observational study in the CML paediatric population, a statistically significant decrease (but of uncertain clinical relevance) in median height standard deviation scores after 12 and 24&#160;months of treatment was reported in two small subsets irrespective of pubertal status or gender. Close monitoring of growth in children under X treatment is recommended (see section 4.8).</p></div>
              </text>
            </section>
            <section>
              <title
                     value="4.5 Interaction with other medicinal products and other forms of interaction"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029809"/>
                  <display
                           value="4.5 Interaction with other medicinal products and other forms of interaction"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Active substances that may <strong>increase</strong> X plasma concentrations</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycin<span style="color: black;"> </span>and telithromycin) could decrease metabolism and increase X concentrations. There was a significant increase in exposure to X (the mean C<sub>max</sub> and AUC of X rose by 26% and 40%, respectively) in healthy subjects when it was co&#8209;administered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering X with inhibitors of the CYP3A4 family.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Active substances that may <strong>decrease</strong> X plasma concentrations</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidone or <em>Hypericum perforatum</em>, also known as St. John&#8217;s Wort) may significantly reduce exposure to X, potentially increasing the risk of therapeutic failure. Pretreatment with multiple doses of rifampicin 600&#160;mg followed by a single 400&#160;mg dose of X resulted in decrease in C<sub>max</sub> and AUC<sub>(0-&#8734;)</sub> by at least 54% and 74%, of the respective values without rifampicin treatment. Similar results were observed in patients with malignant gliomas treated with X while taking enzyme&#8209;inducing anti&#8209;epileptic medicinal products (EIAEDs) such as carbamazepine, oxcarbazepine and phenytoin. The plasma AUC for X decreased by 73% compared to patients not on EIAEDs. Concomitant use of rifampicin or other strong CYP3A4 inducers and X should be avoided.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Active substances that may have their plasma concentration altered by X</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX increases the mean C<sub>max</sub> and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5&#8209;fold, respectively, indicating an inhibition of the CYP3A4 by X. Therefore, caution is recommended when administering X with CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide,<span style="color: black;"> </span>tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel and quinidine). ProductX may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG&#8209;CoA reductase inhibitors, i.e. statins, etc.).</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">Because of known increased risks of bleeding in conjunction with the use of X (e.g. haemorrhage), patients who require anticoagulation should receive low&#8209;molecular&#8209;weight or standard heparin, </span><span style="font-size: 11.0pt; color: black;">instead of coumarin derivatives such as warfarin</span><span style="font-size: 11.0pt;">.</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><em>In vitro</em> X inhibits the cytochrome P450 isoenzyme CYP2D6 activity at concentrations similar to those that affect CYP3A4 activity. ProductX at 400&#160;mg twice daily had an inhibitory effect on CYP2D6&#8209;mediated metoprolol metabolism, with metoprolol C<sub>max</sub> and AUC being increased by approximately 23% (90%CI&#160;[1.16&#8209;1.30]). Dose adjustments do not seem to be necessary when X is co&#8209;administrated with CYP2D6 substrates, however caution is advised for CYP2D6&#160;substrates with a narrow therapeutic window such as metoprolol. In patients treated with metoprolol clinical monitoring should be considered.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><em>In vitro</em>, X inhibits paracetamol O&#8209;glucuronidation with Ki value of 58.5&#160;micromol/l. This inhibition has not been observed <em>in vivo </em>after the administration of X 400&#160;mg and paracetamol 1000&#160;mg. Higher doses of X and paracetamol have not been studied.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Caution should therefore be exercised when using high doses of X and paracetamol concomitantly.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In thyroidectomy patients receiving levothyroxine, the plasma exposure to levothyroxine may be decreased when X is co-administered (see section 4.4). Caution is therefore recommended. However, the mechanism of the observed interaction is presently unknown.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In Ph+&#160;ALL patients, there is clinical experience of co&#8209;administering X with chemotherapy (see section 5.1), but drug-drug interactions between X and chemotherapy regimens are not well characterised. ProductX adverse events, i.e. hepatotoxicity, myelosuppression or others, may increase and it has been reported that concomitant use with L&#8209;asparaginase could be associated with increased hepatotoxicity (see section 4.8). Therefore, the use of X in combination requires special precaution.</p></div>
              </text>
            </section>
            <section>
              <title value="4.6 Fertility, pregnancy and lactation"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029811"/>
                  <display value="4.6 Fertility, pregnancy and lactation"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Women of childbearing potential</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Women of childbearing potential must be advised to use effective contraception during treatment and for at least 15&#160;days after stopping treatment with ProductX CompanyY.</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pregnancy</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">There are limited data on the use of X in pregnant women. There have been post-marketing reports of spontaneous abortions and infant congenital anomalies from women who have taken X. Studies in animals have however shown reproductive toxicity (see section 5.3) and the potential risk for the foetus is unknown. ProductX should not be used during pregnancy unless clearly necessary. If it is used during pregnancy, the patient must be informed of the potential risk to the foetus.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Breast-feeding</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">There is limited information on X distribution on human milk. Studies in two breast-feeding women revealed that both X and its active metabolite can be distributed into human milk. The milk plasma ratio studied in a single patient was determined to be 0.5 for X and 0.9 for the metabolite, suggesting greater distribution of the metabolite into the milk. Considering the combined concentration of X and the metabolite and the maximum daily milk intake by infants, the total exposure would be expected to be low (~10% of a therapeutic dose). However, since the effects of low&#8209;dose exposure of the infant to X are unknown, women should not breast-feed during treatment and for at least 15&#160;days after stopping treatment with ProductX CompanyY.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Fertility</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">In non-clinical studies, the fertility of male and female rats was not affected</span>, although effects on reproductive parameters were observed<span style="color: black;"> (see section 5.3). Studies on patients receiving X and its effect on fertility and gametogenesis have not been performed. Patients who are concerned about their fertility on X treatment should consult with their physician.</span></p></div>
              </text>
            </section>
            <section>
              <title
                     value="4.7 Effects on ability to drive and use machines"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029815"/>
                  <display
                           value="4.7 Effects on ability to drive and use machines"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with X. Therefore, caution should be recommended when driving a car or operating machinery.</p></div>
              </text>
            </section>
            <section>
              <title value="4.8 Undesirable effects"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029816"/>
                  <display value="4.8 Undesirable effects"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Summary of the safety profile</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Patients with advanced stages of malignancies may have numerous confounding medical conditions that make causality of adverse reactions difficult to assess due to the variety of symptoms related to the underlying disease, its progression, and the co-administration of numerous medicinal products.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In clinical trials in CML, drug discontinuation for drug-related adverse reactions was observed in 2.4% of newly diagnosed patients, 4% of patients in late chronic phase after failure of interferon therapy, 4% of patients in accelerated phase after failure of interferon therapy and 5% of blast crisis patients after failure of interferon therapy. In GIST the study drug was discontinued for drug-related adverse reactions in 4% of patients.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The adverse reactions were similar in all indications, with two exceptions. There was more myelosuppression seen in CML patients than in GIST, which is probably due to the underlying disease. In the study in patients with unresectable and/or metastatic GIST, 7 (5%) patients experienced CTC grade&#160;3/4 GI bleeds (3 patients), intra&#8209;tumoural bleeds (3 patients) or both (1 patient). GI tumour sites may have been the source of the GI bleeds (see section 4.4). GI and tumoural bleeding may be serious and sometimes fatal. The most commonly reported (&#8805;&#160;10%) drug-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash. Superficial oedemas were a common finding in all studies and were described primarily as periorbital or lower limb oedemas. However, these oedemas were rarely severe and may be managed with diuretics, other supportive measures, or by reducing the dose of X.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">When X was combined with high dose chemotherapy in Ph+&#160;ALL patients, transient liver toxicity in the form of transaminase elevation and hyperbilirubinaemia were observed. Considering the limited safety database, the adverse events thus far reported in children are consistent with the known safety profile in adult patients with Ph+ ALL. The safety database for children with Ph+ALL is very limited though no new safety concerns have been identified.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Miscellaneous adverse reactions such as pleural effusion, ascites, pulmonary oedema and rapid weight gain with or without superficial oedema may be collectively described as &#8220;fluid retention&#8221;. These reactions can usually be managed by withholding X temporarily and with diuretics and other appropriate supportive care measures. However, some of these reactions may be serious or life-threatening and several patients with blast crisis died with a complex clinical history of pleural effusion, congestive heart failure and renal failure. There were no special safety findings in paediatric clinical trials.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Adverse reactions</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Adverse reactions reported as more than an isolated case are listed below, by system organ class and by frequency. Frequency categories are defined using the following convention: very common (&#8805;1/10), common (&#8805;1/100&#160;to&#160;1/10), uncommon (&#8805;1/1,000&#160;to&#160;1/100), rare (&#8805;1/10,000&#160;to&#160;1/1,000), very rare (1/10,000), not known (cannot be estimated from the available data).</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Adverse reactions and their frequencies are reported in Table 1.</p><p style="margin: 0cm 0cm 0.0001pt 1cm; text-indent: -1cm; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="break-after: avoid; margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"></p><p style="line-height: normal; break-after: avoid; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><table class="MsoNormalTable" style="width: 464.3pt; margin-left: 5.4pt; border-collapse: collapse; border: none;" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Infections and infestations</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Herpes zoster, herpes simplex, nasopharyngitis, pneumonia<sup>1</sup>, sinusitis, cellulitis, upper respiratory tract infection, influenza, urinary tract infection, gastroenteritis, sepsis</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Fungal infection</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hepatitis B reactivation*</p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Neoplasm benign, malignant and unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Tumour lysis syndrome</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Tumour haemorrhage/tumour necrosis*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong><span style="color: black;">Immune system disorders</span></strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Anaphylactic shock*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Very common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Neutropenia, thrombocytopenia, anaemia</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pancytopenia, febrile neutropenia</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Thrombocythaemia, lymphopenia, bone marrow depression, eosinophilia, lymphadenopathy</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Haemolytic anaemia<span style="color: black;">, thrombotic microangiopathy</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Anorexia</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hypokalaemia, increased appetite, hypophosphataemia, decreased appetite, dehydration, gout, hyperuricaemia, hypercalcaemia, hyperglycaemia, hyponatraemia</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hyperkalaemia, hypomagnesaemia</p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Insomnia</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Depression, libido decreased, anxiety</p></td></tr><tr style="height: 12.8pt;"><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Confusional state</p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Nervous system disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Very common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Headache<sup>2</sup></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Dizziness, paraesthesia, taste disturbance, hypoaesthesia</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Migraine, somnolence, syncope, peripheral neuropathy, memory impairment, sciatica, restless leg syndrome, tremor, cerebral haemorrhage</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Increased intracranial pressure, convulsions, optic neuritis</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Cerebral oedema*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Eye disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Eyelid oedema, lacrimation increased, conjunctival haemorrhage, conjunctivitis, dry eye, blurred vision</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Eye irritation, eye pain, orbital oedema, scleral haemorrhage, retinal haemorrhage, blepharitis, macular oedema</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Cataract, glaucoma, papilloedema</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Vitreous haemorrhage*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Vertigo, tinnitus, hearing loss</p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Cardiac disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Palpitations, tachycardia, cardiac failure congestive<sup>3</sup>, pulmonary oedema</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris, pericardial effusion</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Pericarditis*, cardiac tamponade*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Vascular disorders<sup>4</sup></strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Flushing, haemorrhage</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hypertension, haematoma, <span style="color: black;">subdural haematoma, </span>peripheral coldness, hypotension, Raynaud&#8217;s phenomenon</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Thrombosis/embolism*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Dyspnoea, epistaxis, cough</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pleural effusion<sup>5</sup>, pharyngolaryngeal pain, pharyngitis</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pleuritic pain, pulmonary fibrosis, pulmonary hypertension, pulmonary haemorrhage</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Acute respiratory failure<sup>11</sup>*, interstitial lung disease*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Very common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain<sup>6</sup></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Flatulence, abdominal distension, gastro-oesophageal reflux, constipation, dry mouth, gastritis</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Stomatitis, mouth ulceration, gastrointestinal haemorrhage<sup>7</sup>, eructation, melaena, oesophagitis, ascites, gastric ulcer, haematemesis, cheilitis, dysphagia, pancreatitis</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Colitis, ileus, inflammatory bowel disease</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Ileus/intestinal obstruction*, gastrointestinal perforation*, diverticulitis*, gastric antral vascular ectasia (GAVE)*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Increased hepatic enzymes</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hyperbilirubinaemia, hepatitis, jaundice</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Hepatic failure<sup>8</sup>, hepatic necrosis</p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Very common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Periorbital oedema, dermatitis/eczema/rash</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pruritus, face oedema, dry skin, erythema, alopecia, night sweats, photosensitivity reaction</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, dermatitis exfoliative, onychoclasis, folliculitis, petechiae, psoriasis, purpura, skin hyperpigmentation, bullous eruptions, panniculitis<sup>12</sup></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Acute febrile neutrophilic dermatosis (Sweet&#8217;s syndrome), nail discolouration, angioneurotic oedema, rash vesicular, erythema multiforme, leucocytoclastic vasculitis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis (AGEP), pemphigus*</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Palmoplantar erythrodysesthesia syndrome*, lichenoid keratosis*, lichen planus*, toxic epidermal necrolysis*, drug rash with eosinophilia and systemic symptoms (DRESS)*, pseudoporphyria*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Very common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Muscle spasm and cramps, musculoskeletal pain including myalgia<sup>9</sup>, arthralgia, bone pain<sup>10</sup></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Joint swelling</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Joint and muscle stiffness, osteonecrosis*</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Muscular weakness, arthritis, rhabdomyolysis/myopathy</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Growth retardation in children*</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Renal pain, haematuria, renal failure acute, urinary frequency increased</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not known</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Renal failure chronic</span></p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Gynaecomastia, erectile dysfunction, menorrhagia, menstruation irregular, sexual dysfunction, nipple pain, breast enlargement, scrotal oedema</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Haemorrhagic corpus luteum/haemorrhagic ovarian cyst</p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Very common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Fluid retention and oedema, fatigue</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Weakness, pyrexia, anasarca, chills, rigors</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Chest pain, malaise</p></td></tr><tr><td style="width: 464.3pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong>Investigations</strong></p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Very common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Weight increased</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Common</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Weight decreased</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Uncommon</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Blood creatinine increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood alkaline phosphatase increased</p></td></tr><tr><td style="width: 125.9pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Rare</p></td><td style="width: 338.4pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Blood amylase increased</p></td></tr></tbody></table><table class="MsoNormalTable" style="width: 474.8pt; margin-left: 5.4pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="width: 157.35pt; border: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0.2pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0.75pt 0cm 0.0001pt; break-after: avoid; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong><span style="color: #231f20;">(B</span><span style="color: #231f20;">est response rates)</span></strong></p></td><td style="width: 158.75pt; border-top: solid windowtext 1.0pt; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.2pt 49.65pt 0.0001pt 46.25pt; text-align: center; line-height: normal; break-after: avoid; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">ProductX</span></p><p style="margin: 0.75pt 0cm 0.0001pt; text-align: center; break-after: avoid; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">n=553</span></p></td><td style="width: 158.7pt; border: solid windowtext 1.0pt; border-left: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.2pt 37.4pt 0.0001pt 38.05pt; text-align: center; line-height: normal; break-after: avoid; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">I</span><span style="color: #231f20;">F</span><span style="color: #231f20;">N+A</span><span style="color: #231f20;">r</span><span style="color: #231f20;">a</span><span style="color: #231f20;">-</span><span style="color: #231f20;">C</span></p><p style="margin: 0.75pt 0cm 0.0001pt; text-align: center; break-after: avoid; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">n=553</span></p></td></tr><tr><td style="width: 157.35pt; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0.2pt -1pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong><span style="color: #231f20;">H</span><span style="color: #231f20;">aematological </span><span style="color: #231f20;">r</span><span style="color: #231f20;">e</span><span style="color: #231f20;">sponse</span></strong></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">CH</span><span style="color: #231f20;">R rate n (%)</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">&#160;&#160;&#160;&#160;&#160;&#160; [95% CI]</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p></td><td style="width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">534 (96.6%)*</span></p><p style="margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">[94.7%, 97.9%]</span></p></td><td style="width: 158.7pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">313 (56.6%)*</span></p><p style="margin: 0.75pt 0cm 0.0001pt; text-align: center; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">[52.4%, 60.8%]</span></p></td></tr><tr><td style="width: 157.35pt; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong><span style="color: #231f20;">Cytogenetic response</span></strong></p></td><td style="width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p></td><td style="width: 158.7pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p></td></tr><tr><td style="width: 157.35pt; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">Major response n (%)</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">&#160;&#160;&#160;&#160;&#160;&#160; [95% CI]</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">&#160;&#160;&#160;&#160;&#160;&#160; Complete CyR n (%)</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">&#160;&#160;&#160;&#160;&#160;&#160; Partial CyR n (%)</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">&#160;</span></p></td><td style="width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">490 (88.6%)*</span></p><p style="margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">[85.7%, 91.1%]</span></p><p style="margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">456 (82.5%)*</span></p><p style="text-align: center; margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">34 (6.1%)</span></p></td><td style="width: 158.7pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">129 (23.3%)*</span></p><p style="margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">[19.9%, 27.1%]</span></p><p style="margin: 0cm -1pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">64 (11.6%)*</span></p><p style="margin: 0cm -1.15pt 0.0001pt 0cm; text-align: center; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">65 (11.8%)</span></p></td></tr><tr><td style="width: 7.0cm; border: none; border-left: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong><span style="color: #231f20;">Molecular response**</span></strong></p></td><td style="width: 158.75pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">&#160;</span></p></td><td style="width: 117.6pt; border: none; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">&#160;</span></p></td></tr><tr><td style="width: 7.0cm; border-top: none; border-left: solid windowtext 1.0pt; border-bottom: solid windowtext 1.0pt; border-right: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">Major response at 12 months (%)</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">Major response at 24 months (%)</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">Major response at 84 months (%)</span></p></td><td style="width: 158.75pt; border: none; border-bottom: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="2" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">153/305=50.2%</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">73/104=70.2%</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">102/116=87.9%</span></p></td><td style="width: 117.6pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">8/83=9.6%</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">3/12=25%</span></p><p style="margin: 0.75pt 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">3/4=75%</span></p></td></tr><tr><td style="width: 474.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt;" colspan="5" valign="top"><p style="margin: 0cm -1pt 0.0001pt 0cm; line-height: 12.05pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">* p 0.001, Fischer&#8217;s exact test</span></p><p style="margin: 0.3pt -1pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">** molecular response percentages are based on available samples</span></p><p style="margin: 0.2pt -1pt 0.0001pt 0cm; line-height: 13.3pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong><span style="color: #231f20; position: relative; top: .5pt;">H</span><span style="color: #231f20; position: relative; top: .5pt;">aematological </span><span style="color: #231f20; position: relative; top: .5pt;">r</span><span style="color: #231f20; position: relative; top: .5pt;">e</span><span style="color: #231f20; position: relative; top: .5pt;">sponse criteria (all responses to be confirmed after </span></strong><strong>&#8805;<span style="color: #231f20; position: relative; top: .5pt;"> </span><span style="color: #231f20; position: relative; top: .5pt;">4 weeks):</span></strong></p><p style="margin: 0.05pt 25.55pt 0.0001pt 0cm; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: #231f20;">WBC 10 x 10</span><span style="font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;">9</span><span style="color: #231f20;">/l</span><span style="color: #231f20;">, platelet 450 x 10</span><span style="font-size: 7.0pt; color: #231f20; position: relative; top: -5.0pt;">9</span><span style="color: #231f20;">/l</span><span style="color: #231f20;">, myelocyte+metamyelocyte 5% in blood, no blasts and promyelocytes in blood, basophils 20%, no extramedullary involvement</span></p><p style="margin: 0.3pt 17.35pt 0.0001pt 0cm; line-height: 102%; font-size: 11pt; font-family: 'Times New Roman', serif;"><strong><span style="color: #231f20;">C</span><span style="color: #231f20;">ytogenetic response criteria:</span></strong><span style="color: #231f20;"> </span><span style="color: #231f20;">complete (0% Ph+ metaphases), partial (1&#8211;35%), minor (36&#8211;65%) or minimal (66&#8211;95%). A major response (0&#8211;35%) combines both complete and partial responses. <strong>Major molecular response criteria:</strong> in the peripheral blood reduction of &#8805; 3 logarithms in the amount of Bcr&#8209;Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline.</span></p></td></tr></tbody></table></div>
              </text>
              <section>
                <title value="Reporting of suspected adverse reactions"/>
                <code>
                  <coding>
                    <system
                            value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                    <code value="200000029818"/>
                    <display
                             value="Reporting of suspected adverse reactions"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/>
                  <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Content on reporting of suspected adverse reactions</p></div>
                </text>
              </section>
            </section>
            <section>
              <title value="4.9 Overdose"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029819"/>
                  <display value="4.9 Overdose"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">Experience with doses higher than the recommended therapeutic dose is limited. Isolated cases of X overdose have been reported spontaneously and in the literature. In the event of overdose the patient should be observed and appropriate symptomatic treatment given. Generally the reported outcome in these cases was &#8220;improved&#8221; or &#8220;recovered&#8221;. Events that have been reported at different dose ranges are as follows:</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">&#160;</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">Adult population</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">1200&#160;mg to 1600&#160;mg (duration varying between 1 to 10&#160;days): Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite.</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">1800&#160;mg to 3200&#160;mg (as high as 3200&#160;mg daily for 6&#160;days): Weakness, myalgia, increased creatine phosphokinase, increased bilirubin, gastrointestinal pain.</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">6400&#160;mg (single dose): One case reported in the literature of one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, decreased neutrophil count, increased transaminases.</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">8&#160;g to 10&#160;g (single dose): Vomiting and gastrointestinal pain have been reported.</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">&#160;</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">Paediatric population</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">One 3&#8209;year&#8209;old male exposed to a single dose of 400&#160;mg experienced vomiting, diarrhoea and anorexia and another 3&#8209;year&#8209;old male exposed to a single dose of 980&#160;mg experienced decreased white blood cell count and diarrhoea.</span></p><p style="margin: 0cm 0cm 0.0001pt; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11.0pt;">&#160;</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In the event of overdose, the patient should be observed and appropriate supportive treatment given.</p></div>
              </text>
            </section>
          </section>
          <section>
            <title value="5. PHARMACOLOGICAL PROPERTIES"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029821"/>
                <display value="5. PHARMACOLOGICAL PROPERTIES"/>
              </coding>
            </code>
            <section>
              <title value="5.1 Pharmacodynamic properties"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029822"/>
                  <display value="5.1 Pharmacodynamic properties"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pharmacotherapeutic group: Antineoplastic agents, BCR-ABL tyrosine kinase inhibitors, ATC code: L01EA01</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Mechanism of action</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">ProductX is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr&#8209;Abl tyrosine kinase (TK), as well as several receptor TKs: </span>Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, <span style="color: black;">the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta). ProductX can also inhibit cellular events mediated by activation of these receptor kinases.</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pharmacodynamic effects</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr&#8209;Abl tyrosine kinase at the <em>in vitro</em>, cellular and <em>in vivo </em>levels. The compound selectively inhibits proliferation and induces apoptosis in Bcr&#8209;Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and acute lymphoblastic leukaemia (ALL) patients.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p></div>
              </text>
            </section>
            <section>
              <title value="5.2 Pharmacokinetic properties"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029827"/>
                  <display value="5.2 Pharmacokinetic properties"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pharmacokinetics of X</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The pharmacokinetics of X have been evaluated over a dosage range of 25 to 1,000&#160;mg. Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Absorption</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Mean absolute bioavailability for <span style="font-size: 11.0pt; font-family: 'Times New Roman', serif;">the capsule formulation </span>is 98%. There was high between-patient variability in plasma X AUC levels after an oral dose. When given with a high-fat meal, the rate of absorption of X was minimally reduced (11% decrease in C<sub>max</sub> and prolongation of t<sub>max</sub> by 1.5&#160;h), with a small reduction in AUC (7.4%) compared to fasting conditions. The effect of prior gastrointestinal surgery on drug absorption has not been investigated.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Distribution</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">At clinically relevant concentrations of X, binding to plasma proteins was approximately 95% on the basis of <em>in vitro </em>experiments, mostly to albumin and alpha-acid-glycoprotein, with little binding to lipoprotein.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Biotransformation</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The main circulating metabolite in humans is the N&#8209;demethylated piperazine derivative, which shows similar <em>in vitro </em>potency to the parent. The plasma AUC for this metabolite was found to be only 16% of the AUC for X. The plasma protein binding of the N&#8209;demethylated metabolite is similar to that of the parent compound.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC<sub>(0&#8209;48h)</sub>). The remaining circulating radioactivity consisted of a number of minor metabolites.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The <em>in vitro </em>results showed that CYP3A4 was the major human P450 enzyme catalysing the biotransformation of X. Of a panel of potential comedications (acetaminophen, aciclovir, allopurinol, amphotericin, cytarabine, erythromycin, fluconazole, hydroxyurea, norfloxacin, penicillin&#160;V) only erythromycin (IC<sub>50</sub> 50&#160;&#956;M) and fluconazole (IC<sub>50</sub> 118&#160;&#956;M) showed inhibition of X metabolism which could have clinical relevance.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX was shown <em>in vitro </em>to be a competitive inhibitor of marker substrates for CYP2C9, CYP2D6 and CYP3A4/5. K<sub>i</sub> values in human liver microsomes were 27, 7.5 and 7.9&#160;&#181;mol/l, respectively. Maximal plasma concentrations of X in patients are 2&#8209;4&#160;&#181;mol/l, consequently an inhibition of CYP2D6 and/or CYP3A4/5&#8209;mediated metabolism of co&#8209;administered drugs is possible. ProductX did not interfere with the biotransformation of 5&#8209;fluorouracil, but it inhibited paclitaxel metabolism as a result of competitive inhibition of CYP2C8 (K<sub>i&#160;</sub>=&#160;34.7&#160;&#956;M). This K<sub>i</sub> value is far higher than the expected plasma levels of X in patients; consequently no interaction is expected upon co&#8209;administration of either 5&#8209;fluorouracil or paclitaxel and X.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Elimination</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Based on the recovery of compound(s) after an oral <sup>14</sup>C&#8209;labelled dose of X, approximately 81% of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). Unchanged X accounted for 25% of the dose (5% urine, 20% faeces), the remainder being metabolites.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Plasma pharmacokinetics</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Following oral administration in healthy volunteers, the t<sub>&#189;</sub> was approximately 18&#160;h, suggesting that once&#8209;daily dosing is appropriate. The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25&#8209;1,000&#160;mg X after oral administration. There was no change in the kinetics of X on repeated dosing, and accumulation was 1.5&#8209;2.5&#8209;fold at steady state when dosed once daily.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pharmacokinetics in GIST patients</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In patients with GIST steady-state exposure was 1.5-fold higher than that observed for CML patients for the same dosage (400 mg daily). Based on preliminary population pharmacokinetic analysis in GIST patients, there were three variables (albumin, WBC and bilirubin) found to have a statistically significant relationship with X pharmacokinetics. Decreased values of albumin caused a reduced clearance (CL/f); and higher levels of WBC led to a reduction of CL/f. However, these associations are not sufficiently pronounced to warrant dose adjustment. In this patient population, the presence of hepatic metastases could potentially lead to hepatic insufficiency and reduced metabolism.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Population pharmacokinetics</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Based on population pharmacokinetic analysis in CML patients, there was a small effect of age on the volume of distribution (12% increase in patients&#160;>&#160;65 years old). This change is not thought to be clinically significant. The effect of bodyweight on the clearance of X is such that for a patient weighing 50&#160;kg the mean clearance is expected to be 8.5&#160;l/h, while for a patient weighing 100&#160;kg the clearance will rise to 11.8&#160;l/h. These changes are not considered sufficient to warrant dose adjustment based on kg bodyweight. There is no effect of gender on the kinetics of X.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pharmacokinetics in paediatric population</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">As in adult patients, X was rapidly absorbed after oral administration in paediatric patients in both phase I and phase II studies. Dosing in children at 260 and 340&#160;mg/m<sup>2</sup>/day achieved the same exposure, respectively, as doses of 400&#160;mg and 600&#160;mg in adult patients. The comparison of AUC<sub>(0&#8209;24) </sub>on day 8 and day 1 at the 340&#160;mg/m<sup>2</sup>/day dose level revealed a 1.7&#8209;fold drug accumulation after repeated once-daily dosing.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Based on pooled population pharmacokinetic analysis in paediatric patients with haematological disorders (CML, Ph+ALL, or other haematological disorders treated with X), clearance of X increases with increasing body surface area (BSA). After correcting for the BSA effect, other demographics such as age, body weight and body mass index did not have clinically significant effects on the exposure of X. The analysis confirmed that exposure of X in paediatric patients receiving 260&#160;mg/m<sup>2</sup> once daily (not exceeding 400&#160;mg once daily) or 340&#160;mg/m<sup>2</sup> once daily (not exceeding 600&#160;mg once daily) were similar to those in adult patients who received X 400&#160;mg or 600&#160;mg once daily.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Organ function impairment</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX and its metabolites are not excreted via the kidney to a significant extent. Patients with mild and moderate impairment of renal function appear to have a higher plasma exposure than patients with normal renal function. The increase is approximately 1.5 to 2&#8209;fold, corresponding to a 1.5&#8209;fold elevation of plasma AGP, to which X binds strongly. The free drug clearance of X is probably similar between patients with renal impairment and those with normal renal function, since renal excretion represents only a minor elimination pathway for X (see sections 4.2 and 4.4).</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Although the results of pharmacokinetic analysis showed that there is considerable inter-subject variation, the mean exposure to X did not increase in patients with varying degrees of liver dysfunction as compared to patients with normal liver function (see sections 4.2, 4.4 and 4.8).</p></div>
              </text>
            </section>
            <section>
              <title value="5.3 Preclinical safety data"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029834"/>
                  <display value="5.3 Preclinical safety data"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The preclinical safety profile of X was assessed in rats, dogs, monkeys and rabbits.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Multiple dose toxicity studies revealed mild to moderate haematological changes in rats, dogs and monkeys, accompanied by bone marrow changes in rats and dogs.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The liver was a target organ in rats and dogs. Mild to moderate increases in transaminases and slight decreases in cholesterol, triglycerides, total protein and albumin levels were observed in both species. No histopathological changes were seen in rat liver. Severe liver toxicity was observed in dogs treated for 2 weeks, with elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Renal toxicity was observed in monkeys treated for 2 weeks, with focal mineralisation and dilation of the renal tubules and tubular nephrosis. Increased blood urea nitrogen (BUN) and creatinine were observed in several of these animals. In rats, hyperplasia of the transitional epithelium in the renal papilla and in the urinary bladder was observed at doses&#160;&#8805;&#160;6&#160;mg/kg in the 13&#8209;week study, without changes in serum or urinary parameters. An increased rate of opportunistic infections was observed with chronic X treatment.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In a 39&#8209;week monkey study, no NOAEL (no observed adverse effect level) was established at the lowest dose of 15&#160;mg/kg, approximately one-third the maximum human dose of 800&#160;mg based on body surface. Treatment resulted in worsening of normally suppressed malarial infections in these animals.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX was not considered genotoxic when tested in an <em>in vitro </em>bacterial cell assay (Ames test), an <em>in vitro </em>mammalian cell assay (mouse lymphoma) and an <em>in vivo </em>rat micronucleus test. Positive genotoxic effects were obtained for X in an <em>in vitro </em>mammalian cell assay (Chinese hamster ovary) for clastogenicity (chromosome aberration) in the presence of metabolic activation. Two intermediates of the manufacturing process, which are also present in the final product, are positive for mutagenesis in the Ames assay. One of these intermediates was also positive in the mouse lymphoma assay.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In a study of fertility, in male rats dosed for 70 days prior to mating, testicular and epididymal weights and percent motile sperm were decreased at 60&#160;mg/kg, approximately equal to the maximum clinical dose of 800&#160;mg/day, based on body surface area. This was not seen at doses&#160;&#8804;&#160;20&#160;mg/kg. A slight to moderate reduction in spermatogenesis was also observed in the dog at oral doses&#160;&#8805;&#160;30&#160;mg/kg. When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females. At a dose of 60&#160;mg/kg, female rats had significant post&#8209;implantation foetal loss and a reduced number of live foetuses. This was not seen at doses&#160;&#8804;&#160;20&#160;mg/kg.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In an oral pre- and postnatal development study in rats, red vaginal discharge was noted in the 45&#160;mg/kg/day group on either day 14 or day 15 of gestation. At the same dose, the number of stillborn pups as well as those dying between postpartum days 0 and 4 was increased. In the F<sub>1</sub> offspring, at the same dose level, mean body weights were reduced from birth until terminal sacrifice and the number of litters achieving criterion for preputial separation was slightly decreased. F<sub>1</sub> fertility was not affected, while an increased number of resorptions and a decreased number of viable foetuses was noted at 45&#160;mg/kg/day. The no observed effect level (NOEL) for both the maternal animals and the F<sub>1</sub> generation was 15&#160;mg/kg/day (one quarter of the maximum human dose of 800&#160;mg).</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX was teratogenic in rats when administered during organogenesis at doses&#160;&#8805;&#160;100&#160;mg/kg, approximately equal to the maximum clinical dose of 800&#160;mg/day, based on body surface area. Teratogenic effects included exencephaly or encephalocele, absent/reduced frontal and absent parietal bones. These effects were not seen at doses&#160;&#8804;&#160;30&#160;mg/kg.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">No new target organs were identified in the rat juvenile development toxicology study (day&#160;10 to 70 postpartum) with respect to the known target organs in adult rats. In the juvenile toxicology study, effects upon growth, delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2&#160;times the average paediatric exposure at the highest recommended dose of 340&#160;mg/m<sup>2</sup>. In addition, mortality was observed in juvenile animals (around weaning phase) at approximately 2&#160;times the average paediatric exposure at the highest recommended dose of 340&#160;mg/m<sup>2</sup>.</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">In the 2&#8209;year rat carcinogenicity study administration of X at 15, 30 and 60&#160;mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60&#160;mg/kg/day and females at &#8805;30&#160;mg/kg/day. Histopathological examination of decedents revealed cardiomyopathy (both sexes), chronic progressive nephropathy (females) and preputial gland papilloma as principal causes of death or reasons for sacrifice. Target organs for neoplastic changes were the kidneys, urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non&#8209;glandular stomach.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Papilloma/carcinoma of the preputial/clitoral gland were noted from 30&#160;mg/kg/day onwards, representing approximately 0.5 or 0.3 times the human daily exposure (based on AUC) at 400&#160;mg/day or 800&#160;mg/day, respectively, and 0.4 times the daily exposure in children (based on AUC) at 340&#160;mg/m<sup>2</sup>/day. The no observed effect level (NOEL) was 15&#160;mg/kg/day. The renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumours of the adrenal glands and the non&#8209;glandular stomach papillomas/carcinomas were noted at 60&#160;mg/kg/day, representing approximately 1.7 or 1 times the human daily exposure (based on AUC) at 400&#160;mg/day or 800&#160;mg/day, respectively, and 1.2 times the daily exposure in children (based on AUC) at 340&#160;mg/m<sup>2</sup>/day. The no observed effect level (NOEL) was 30&#160;mg/kg/day.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">The mechanism and relevance of these findings in the rat carcinogenicity study for humans are not yet clarified.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Non&#8209;neoplastic lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth. The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.</p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">The active substance X demonstrates an environmental risk for sediment organisms.</span></p></div>
              </text>
            </section>
          </section>
          <section>
            <title value="6. PHARMACEUTICAL PARTICULARS"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029836"/>
                <display value="6. PHARMACEUTICAL PARTICULARS"/>
              </coding>
            </code>
            <section>
              <title value="6.1 List of excipients"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029837"/>
                  <display value="6.1 List of excipients"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Capsule content</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Mannitol</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Crospovidone</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Magnesium stearate</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Silica colloidal, anhydrous</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Capsule shell</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Gelatin</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Titanium dioxide (E171)</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Iron oxide, yellow (E172)</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Iron oxide, red (E172)</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">&#160;</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Printing ink</span></p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Shellac</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Iron oxide black (E172)</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Propylene glycol</p></div>
              </text>
            </section>
            <section>
              <title value="6.2 Incompatibilities"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029838"/>
                  <display value="6.2 Incompatibilities"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not applicable.</p></div>
              </text>
            </section>
            <section>
              <title value="6.3 Shelf life"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029839"/>
                  <display value="6.3 Shelf life"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">2 years</p></div>
              </text>
            </section>
            <section>
              <title value="6.4 Special precautions for storage"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029840"/>
                  <display value="6.4 Special precautions for storage"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">This medicinal product does not require any special storage conditions.</p></div>
              </text>
            </section>
            <section>
              <title value="6.5 Nature and contents of container"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029841"/>
                  <display
                           value="6.5 Nature and contents of container [and special equipment for use, administration or implantation]"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="margin: 0cm 0cm 0.0001pt; line-height: 13pt; font-size: 11pt; font-family: 'Times New Roman', serif;">PVC/PE/PVdC/PE/PVC//Al blisters</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">OPA/Al/PVC//Al blisters</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY 100&#160;mg hard capsules</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pack sizes of 60 or 120, hard capsules in blisters.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pack sizes of 20x1, 60x1, 120x1 or 180x1 hard capsules in perforated unit dose blisters.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">ProductX CompanyY 400&#160;mg hard capsules</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pack sizes of 30 or 90 hard capsules in blisters.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Pack sizes of 30x1 or 90x1 hard capsules in perforated unit dose blisters.</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">&#160;</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Not all pack sizes may be marketed.</p></div>
              </text>
            </section>
            <section>
              <title value="6.6 Special precautions for disposal"/>
              <code>
                <coding>
                  <system
                          value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                  <code value="200000029842"/>
                  <display
                           value="6.6 Special precautions for disposal [and other handling]"/>
                </coding>
              </code>
              <text>
                <status value="additional"/>
                <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;"><span style="color: black;">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</span></p></div>
              </text>
            </section>
          </section>
          <section>
            <title value="7. MARKETING AUTHORISATION HOLDER"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029844"/>
                <display value="7. MARKETING AUTHORISATION HOLDER"/>
              </coding>
            </code>
            <text>
              <status value="additional"/>
              <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Company Y</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Company Street Address</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Company Postal Code</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Country</p></div>
            </text>
          </section>
          <section>
            <title value="8. MARKETING AUTHORISATION NUMBER(S)"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029845"/>
                <display value="8. MARKETING AUTHORISATION NUMBER(S)"/>
              </coding>
            </code>
            <text>
              <status value="additional"/>
              <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">EU/1/12/808/YYY-YYY</p></div>
            </text>
          </section>
          <section>
            <title
                   value="9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029846"/>
                <display
                         value="9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
              </coding>
            </code>
            <text>
              <status value="additional"/>
              <div xmlns="http://www.w3.org/1999/xhtml"><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Date of first authorisation: 08 January 2013</p><p style="line-height: normal; margin: 0cm 0cm 0.0001pt; font-size: 11pt; font-family: 'Times New Roman', serif;">Date of latest renewal: 18 September 2017</p></div>
            </text>
          </section>
          <section>
            <title value="10. DATE OF REVISION OF THE TEXT"/>
            <code>
              <coding>
                <system
                        value="http://ema.europa.eu/fhir/CodeSystem/200000029659"/>
                <code value="200000029847"/>
                <display value="10. DATE OF REVISION OF THE TEXT"/>
              </coding>
            </code>
            <text>
              <status value="additional"/>
              <div xmlns="http://www.w3.org/1999/xhtml"><p>&#160;</p><p style="margin: 0cm -0.1pt 0.0001pt 0cm; line-height: normal; font-size: 11pt; font-family: 'Times New Roman', serif;">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu</p></div>
            </text>
          </section>
        </section>
      </Composition>
    </resource>
  </entry>
</Bundle>